Phase 2 clinical study of ban2401 in early alzheimer’s diseasehttp://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-detailed-results-phase-ii-clinical by technological • 8 years ago 1 0 8 years agoINinvestors.biogen.com